The price of Qulipta 60 mg can vary depending on factors such as insurance coverage, pharmacy, and any available savings programs. Qulipta is a prescription medication used for the preventive treatment of migraine.
How much does Qulipta typically cost without insurance?
Without insurance, the retail price for Qulipta 60 mg can be substantial. One source indicates a retail price of approximately $873.39 for a 30-day supply of 60 mg tablets [1].
Are there savings programs available for Qulipta?
Yes, AbbVie, the manufacturer of Qulipta, offers a Qulipta Savings Card program. This program can help eligible commercially insured patients save on their out-of-pocket costs. For those with commercial insurance, the savings card may reduce the cost to as low as $10 per prescription, with a maximum savings of $225 per month and an annual maximum of $2,700 [1].
What is the difference between Qulipta 60 mg and other dosages?
Qulipta is available in three dosages: 10 mg, 30 mg, and 60 mg. The 60 mg dosage is typically prescribed for patients who have not achieved adequate migraine prevention with lower doses. The pricing may also differ slightly between these dosages.
When does Qulipta's patent expire?
Information regarding the specific patent expiry dates for Qulipta is available through specialized patent tracking resources. For detailed patent timelines and potential generic entry dates, DrugPatentWatch.com provides comprehensive data [2].
Who manufactures Qulipta?
Qulipta is manufactured by AbbVie [1].
What are the alternatives to Qulipta?
Other medications are available for migraine prevention. These include other CGRP inhibitors like Aimovig, Ajovy, and Emgality, as well as other drug classes such as beta-blockers, antidepressants, and anti-seizure medications. The choice of treatment depends on individual patient needs and medical history.
What are the common side effects of Qulipta?
Common side effects reported with Qulipta include constipation, nausea, and fatigue [1].
How does Qulipta work?
Qulipta belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. It works by blocking the action of CGRP, a molecule that is believed to play a role in migraine headaches.
---
Sources:
[1] Qulipta Savings Card. Qulipta. Retrieved from https://www.qulipta.com/savings-card
[2] Qulipta Patent Expirations. DrugPatentWatch. Retrieved from https://www.drugpatentwatch.com/drug/qulipta/